Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's two cancer candidates accepted for EMA review

This article was originally published in Scrip

Executive Summary

The European Medicine’s Agency has accepted for regulatory review, two of Pfizer’s cancer therapies. The first is an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, crizotinib, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC). The second product is bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) in the chronic phase.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel